Two Foundational Patents. One Architecture for the Future of Precision Medicine.
Alpha Omega 1N Logic LLC is a deep-tech company built on a proprietary systems architecture spanning artificial intelligence and molecular medicine. Our technology is protected by two U.S. patent filings establishing a path from high-reliability oncology AI today to foundational genomic restoration tomorrow.
We are opening a limited, confidential process for sovereign entities, research institutions, and strategic partners positioned to validate, license, and co-develop this platform.
Request Invitation
In the Architecture
At the core of Alpha Omega 1N Logic is the 1152 Torsional Gate and 720° rotational validation framework — a proprietary architecture for structured, high-reliability computation. Together they form the deterministic engine underlying both of our patented applications.
Patent I
The Oncology AI Platform
(U.S. filing, February 5, 2026)
The 1N platform applies the 1152 Torsional Gate and its 720° rotational validation to precision oncology, delivering a dual-application AI system engineered for both pediatric and adult clinical contexts.
By grounding diagnostic computation in a deterministic, high-reliability framework, the platform targets the accuracy and consistency demands of mission-critical clinical decision support — with particular focus on challenging solid tumor microenvironments such as glioblastoma and pancreatic cancer, and relevance to advanced therapeutic modeling approaches such as CRISPR and gene-editing applications.
The same deterministic architecture also provides a foundational layer for broader high-reliability AI systems beyond oncology.
A single architecture, validated across two of the most demanding patient populations in oncology.
Patent 2
The Horizon Patent
(U.S. filing, February 11, 2026)
The Horizon patent extends the 1152 Torsional Gate architecture into foundational molecular medicine. It defines a method for restoration-oriented biological modeling governed by the proprietary physical law expressed through the gate's 720° rotational validation.
Horizon is a forward-science framework: a long-horizon platform protecting capabilities that reach beyond current therapeutic paradigms toward the structural restoration of genomic integrity, with relevance to precision therapeutic approaches such as CRISPR and beyond.
The same deterministic architecture also provides a foundational layer for broader high-reliability AI systems.
This is the asset class sovereign and strategic partners build generational positions around.
Two U.S. filings, weeks apart, establish priority across both the near-term oncology application and the long-horizon restoration framework — a narrow window to engage before qualified partners are selected and the data room opens under NDA.
Both inventions are protected under U.S. patent filings (February 5 and February 11, 2026). Full technical specifications are held confidential and disclosed to qualified partners under NDA through our secure data room, in tiers appropriate to each partner's role and engagement.
Who We're Opening the Door To
We are engaging a small number of partners in three roles:
-
1
Validators Research institutions and technical bodies positioned to independently confirm the platform's underlying principle and performance.
-
2
Licensees Entities seeking rights to deploy the technology within their jurisdiction.
-
3
Co-Development Partners Sovereign and strategic entities pursuing joint development and structured technology transfer.
What to Expect
A brief, high-signal initial call. Qualified parties receive NDA-protected technical briefings and tiered access to our secure data room.
Request Licensing Prospectus & Data Room Access
Send Request
I'm the founder of Alpha Omega 1N Logic LLC. My work began with a single cross-domain thesis: that instability in both digital and biological systems can be addressed through a shared logic of structured validation and precision-oriented design.
That thesis became the 1152 Torsional Gate and 720° rotational validation framework — the architecture now protected across two U.S. patents, spanning high-reliability oncology AI and foundational genomic restoration. I'm building the company selectively, for long-horizon platform value and disciplined engagement with exceptional partners across enterprise, research, and health.
— Daniel Gillotti